Arcturus Therapeutics Holdings Inc (ARCT)

Etorro trading 970x250
Arcturus Therapeutics Holdings Inc (ARCT) Logo

About Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology. Its preclinical drug discovery and development programs include LUNAR-OTC development program that is developing mRNA compounds to treat ornithine transcarbamylase (OTC) deficiency; LUNAR-CF program, which is developing mRNA compounds to replace dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein in cystic fibrosis (CF) patients; and LUNAR-CV and LUNAR-MD that are internal research programs focused on target validation of multiple pipeline LUNAR-mRNA program candidates. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 182 patents and patent applications, issued in the United States, China, Europe, Japan, and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19, a vaccine to address the Coronavirus outbreak; and Catalent, Inc. to support the expected manufacture of Arcturus’ COVID-19 mRNA vaccine candidate (LUNAR-COV19. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California. Address: 10628 Science Center Drive, San Diego, CA, United States, 92121

Arcturus Therapeutics Holdings Inc News and around…

Latest news about Arcturus Therapeutics Holdings Inc (ARCT) common stock and company :

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
21 Oct, 2021 FinancialContent

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

3 Beaten-Down Stocks Cathie Wood Is Buying That Wall Street Thinks Will Skyrocket
19 Oct, 2021 FinancialContent

These growth stocks could rebound in a big way.

Two Stock Picks From the Woodstock of Micro-Caps
18 Oct, 2021 Yahoo! Finance

The annual LD Micro Conference was held recently and Real Money's Jim Collins was on hand to evaluate potential micro-cap stock winners. "It's the Woodstock of micro-capitalism," Collins wrote in Real Money.

Cathie Wood Just Bought Shares of This Vaccine Underdog. Should You?
15 Oct, 2021 FinancialContent

The company disappointed last year, but things may be turning around.

Stock Upgrades: Arcturus Therapeutics Shows Rising Relative Strength
15 Oct, 2021 FinancialContent

A Relative Strength Rating upgrade for Arcturus Therapeutics shows improving technical performance.

These Microcaps Are Making Some Big Noise
15 Oct, 2021 Yahoo! Finance

LD Micro's fearless leader, Chris Lahiji, had to shut things down last year, owing to the pandemic, but, unlike other conferences scheduled for the fourth quarter, decided to go to hybrid mode this year instead of fully remote. CEOs, CFOs, buy-siders, individual investors ... everyone shows up to LD Micro.

Bullish Two Hundred Day Moving Average Cross - ARCT
13 Oct, 2021 FinancialContent

In trading on Wednesday, shares of Arcturus Therapeutics Holdings Inc (ARCT) crossed above their 200 day moving average of $46.02, changing hands as high as $46.25 per share. Arcturus Therapeutics Holdings Inc shares are currently trading up about 2.2% on the day..

Stocks Showing Improved Relative Strength: Arcturus Therapeutics
13 Oct, 2021 FinancialContent

A Relative Strength Rating upgrade for Arcturus Therapeutics shows improving technical performance. Will it continue?

Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other
12 Oct, 2021 FinancialContent

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Vietnam Ministry of Health has approved initiation of the Phase 3b part of the placebo-controlled, observer-blind Phase 1/2/3 clinical trial of ARCT-154 self-replicating RNA vaccine targeting the SARS-CoV-2 delta variant and other variants of concern. Arcturus Therapeutics and Vinbiocare remain on track to potentially file an Emergency Use Authorization (EUA) for ARCT-154 in Vietnam in December 2021.

Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
12 Oct, 2021 Yahoo! Finance

SAN DIEGO, October 12, 2021--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Vietnam Ministry of Health has approved initiation of the Phase 3b part of the placebo-controlled, observer-blind Phase 1/2/3 clinical trial of ARCT-154 self-replicating RNA vacc

Here are Citi’s 10 fresh ways to play disruption — including psychedelic drugs
12 Oct, 2021 FinancialContent

NFTs, psychedelic drugs, artificial intelligence in airlines. Citi's exhaustive look at 10 new disruptive innovation ideas includes a batch of stock ideas.

Analysts Expect 42% Gains Ahead For The Holdings of WDNA
07 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the WisdomTree BioRevolution Fund ETF (WDNA), we found that the implied analyst target price for the ETF based upon its underlying holdings is $35.26 per unit.

Merck Keeps M&A Mode On With Mirati, Biogen, mRNA Companies On Radar: FT
06 Oct, 2021 FinancialContent

Merck & Co Inc(NYSE: MRK) remains in a deal-hunting mode despite its recent $11.5 billion acquisition of ...

After COVID-19, Could This Be the Next Billion-Dollar Vaccine Market?
04 Oct, 2021 FinancialContent

Three healthcare giants are vying for the prize.

Arcturus Therapeutics Meets 80-Plus Relative Strength Rating Benchmark
01 Oct, 2021 FinancialContent

A Relative Strength Rating upgrade for Arcturus Therapeutics shows improving technical performance.

Arcturus Therapeutics Stock Sees Relative Strength Rating Rise To 83
29 Sep, 2021 Yahoo! Finance

One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Arcturus Therapeutics stock cleared that benchmark Wednesday, with a jump from 73 to 83 Wednesday. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

Stocks To Watch: Arcturus Therapeutics Sees Relative Strength Rating Rise To 83
29 Sep, 2021 FinancialContent

Arcturus Therapeutics sees its Relative Strength Rating hit the 80-plus level.

Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration
22 Sep, 2021 FinancialContent

Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration

Vietnam's Health Ministry Approves Phase 2, Phase 3 Cohorts Of Arcturus' COVID-19 Vaccine Trial
22 Sep, 2021 FinancialContent

Arcturus Therapeutics Holdings Inc(NASDAQ: ARCT) hascompleted dosing of 100 subjectsfor the Phase 1 portion of the ...

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
22 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and O
22 Sep, 2021 FinancialContent

Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine

Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
22 Sep, 2021 Yahoo! Finance

SAN DIEGO, September 22, 2021--Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine

Stocks Showing Rising Market Leadership: Arcturus Therapeutics Earns 81 RS Rating
22 Sep, 2021 FinancialContent

Arcturus Therapeutics sees its Relative Strength Rating enter the 80-plus level.

Arcturus Therapeutics Earnings Perspective: Return On Capital Employed
15 Sep, 2021 FinancialContent

According to Benzinga Pro data, during Q2, Arcturus Therapeutics (NASDAQ:ARCT) posted sales of $2.00 million. Earnings were up 6.84%, ...

7 Busted Biotech Stocks Due for a Rebound
08 Sep, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Buying biotech stocks while they're down is rewarding once they post positive clinical results, setting the stage for a big rally. The post 7 Busted Biotech Stocks Due for a Rebound appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
08 Sep, 2021 FinancialContent

Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
07 Sep, 2021 FinancialContent

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

3 mRNA Stocks Not Named Moderna You Might Want to Check Out
05 Sep, 2021 FinancialContent

Moderna isn't the only biotech focused on messenger RNA.

Expert Ratings For Arcturus Therapeutics
31 Aug, 2021 FinancialContent

Within the last quarter, Arcturus Therapeutics (NASDAQ:ARCT) has observed the following analyst ratings: Bullish Somewhat ...

Analyst Ratings For Arcturus Therapeutics
25 Aug, 2021 FinancialContent

Analysts have provided the following ratings for Arcturus Therapeutics (NASDAQ:ARCT) within the last quarter: ...

Arcturus Therapeutics Holdings Inc (ARCT) is a NASDAQ Common Stock listed in , ,

970x250